Survivin and PSMA loaded dendritic cell vaccine for the treatment of prostate cancer

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 6, 2015, Pages 827-835

  Xi, Hai Bo ^a   Wang, Gong Xian ^a   Fu, Bin ^a   Liu, Wei Peng ^a   Li, Yu ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Autologous cellular immunotherapy; Dendritic cell vaccine; Prostate cancer; Prostate specific membrane antigen; Survivin

Indexed keywords

DENDRITIC CELL VACCINE; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT SURVIVIN; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CANCER VACCINE; INHIBITOR OF APOPTOSIS PROTEIN; PROSTATE SPECIFIC ANTIGEN; TAXOID; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MALE; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; DENDRITIC CELL; IMMUNOLOGY; MIDDLE AGED; PROSTATIC NEOPLASMS; VACCINATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY, DELAYED; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; VACCINATION;

EID: 84936885250     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00518     Document Type: Article

References (41)

1. Goxe B, Latour N, Chokri M, Abastado JP, Salcedo M. Simpliiied method to generate large quantities of dendritic cells suitable for clinical applications. Immunol. Invest., 29, 319-336 (2000).
2. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp. Med., 180, 83-93 (1994).
3. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol. Methods, 196, 137-151 (1996).
4. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. I Exp. Med., 179, 1109-1118 (1994).
5. He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoproteetion against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother., 50, 31-40 (2001).
6. Mayordomo Jl, Zorina T, Storkus W.J, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, lldstad ST, Martin Kast W, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1, 1297-1302 (1995).
7. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp. Med., 186, 1183-1187 (1997).
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature, 392, 245-252 (1998).
9. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2, 52-58 (1996).
10. Nestle FO, Banchereau J, Hart D. Dendritic cells. On the move from bench to bedside. Nat. Med., 7, 761-765 (2001).
11. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res., 6, 1755-1766 (2000).
12. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin. Oncol., 21, 2415-2432 (2003).
13. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl. J Med., 351, 1513-1520 (2004).
14. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenbcrgcr MA; TAX 327 Investigators. Docetaxcl plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl. J Med, 351, 1502-1512 (2004).
15. Doehn C, Bohmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer vaccines: current status and future potential. BioDrugs, 22, 71-84 (2008).
16. Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev. Recent Clin. Trials, 2, 182-190 (2007).
17. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marehisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-584 (1998).
18. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3, 917-921 (1997).
19. Grossman D, MeNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest. Dermatol., 113, 1076-1081 (1999).
20. Schmidt SM, Sehag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood, 102, 571-576 (2003).
21. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood, 96, 1921-1925 (2000).
22. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene, 19, 617-623 (2000).
23. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl. J Med., 341, 452-453 (1999).
24. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol. Lett., 76, 169-173 (2001).
25. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res., 60, 4845-4849 (2000).
26. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int. J Cancer, 108, 937-941 (2004).
27. Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, Richter K, Lobel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate, 66, 811-821 (2006).
28. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl. J Med., 363, 411-422 (2010).
29. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev., 35, 553-562 (2009).
30. Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. J Vis. Exp., 2013, e50085 (2013).
31. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk HD. T-cell epitope mapping by flow cytometry. Nat. Med., 4, 975-978 (1998).
32. Bapsy PP, Sharan B, Kumar C, Das RP, Rangaraian B, Jain M, Suresh Attili VS, Subramanian S, Aggarwal S, Srivastava M, Vaid A. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy, 16, 234-244 (2014).
33. Bravery CA, Carmen J, Fong T, Oprea W, Hoogendoorn KH, Woda J, Burger SR, Rowley JA, Bonyhadi ML, Van't Hof W. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy, 15, 9-19 .e9 (2013).
34. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleuccl-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology, 81, 1297-1302 (2013).
35. Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J Cancer, 119, 2428-2434 (2006).
36. Waeckerle-Men Y, Uetz-von AE, Fopp M, von Moos R, Bohme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunotlter., 55, 1524-1533 (2006).
37. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate, 40, 125-129 (1999).
38. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br. J. Cancer, 93, 749-756 (2005).
39. Youlin K, Li Z, Xin G, Mingchao X, Xiuheng L, Xiaodong W. Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-IBBL. Hum. Vaccin. Immunother., 9, -772 (2013).
40. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Ray-makers R, Schaap N, Dolstra H. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol. Immunother., 62, 1381-1392 (2013).
41. Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J, Palucka AK. Cross-priming of cyclin B1, MUC-1 and survivin-specif1c CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res., 8, R65 (2006).